drugset
drugset / Trial / NCT00629876

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

NCT00629876 ↗

Phase 1 Terminated 2 enrolled Takeda Affymax · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of peginesatide used to treat anemia in subjects diagnosed with recurrent non-small cell lung cancer, breast cancer or prostate cancer and who also receiving a taxane chemotherapy.

Timeline

Start
2008-01
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject peginesatide Peptide 0.075 mg/kg Subcutaneous
Subject peginesatide Peptide 0.1 mg/kg Subcutaneous
Subject peginesatide Peptide 0.125 mg/kg Subcutaneous
Subject peginesatide Peptide 0.15 mg/kg Subcutaneous
Subject peginesatide Peptide 0.175 mg/kg Subcutaneous
Subject peginesatide Peptide 0.2 mg/kg Subcutaneous
Subject peginesatide Peptide 0.225 mg/kg Subcutaneous
Subject peginesatide Peptide 0.25 mg/kg Subcutaneous

Indications

anemia